Month: December 2017

China launches „100,000 Genomes Project“

The project will cover major areas of China, focussing on the dominant Han ethnic group but also including nine ethnic minorities with a population of 5 million or more. A major goal is to study transformation from health to disease, environmental impacts, and the interactions between environmental factors and genes, and its influence on people’s health. The study is aimed to provide references for medical research or clinical diagnosis and treatment of diseases in China. The entire process of sequencing and analysis of the project is scheduled to be completed within four years. Chief Scientist is WANG Yadong, Harbin Institute of Technology. China Bio news release, December 29, 2017

China’s blood product market size is about 24 billion Yuan, HSA dominates but factor VIII was 6.3 %

The Chinese blood market, with liberalized price control, grew by 16.7 % from 2015 to 2016. It is served by 28 companies which operate about 200 collection stations. There are 11 types of blood products of which human serum albumin is 54 %, human immunoglobulins 24 %. Factor VIII accounted for 6.3 % of blood products in 2016. Many more details are provided in the article. China Bio news release, December 28, 2017

National GenBank opens affiliation at Suzhou BioBAY

The National GenBank with headquarters in Shenzhen will eventually integrate other regional centers already established in China. Suzhou Biological Sample Bank (National Bank of Suzhou Library), formerly known as Suzhou City Serum (Gene) Library, was a project of Suzhou Municipal Government started in 2010; its design stems from a 2004 China-Britain chronic disease prospective study. As of November 30, 2017, a total of 145,742 samples were stored in the library, including 2005 whole-blood samples of severe pneumonia. China Bio news release, December 26, 2017

Chinese researchers believe self-developed CAR-T therapy to be approved within 3 years at a prize within 100,000 Yuan

According to QIAN Qijun, director of the Shanghai Cell Therapy Engineering Research Center, China will have at least a 20 companies or institutions to start CAR-T clinical trials soon, as many funds have been or are being flooded into the field of cellular immunotherapy. According to Founder Securities, at present there are more than 20 domestic enterprises and hospitals which participate in R&D of CAR-T cell therapy, and the number of CAR-T cell therapy clinical trials registered by domestic R & D units has reached over 100. China Bio news release, December 22, 2017

CAS Tianjin Institute of Industrial Biotechnology improves CRISPR/Cas9 genome editing for Corynebacterium glutamicum

The Systems and Synthetic Biotechnology Research Team around MA Yanhe at CAS TIB has developed a versatile CRISPR/Cas9 genome editing toolbox for C. glutamicum. Cas9 and gRNA expression cassettes were reconstituted to combat Cas9 toxicity and facilitate effective termination of gRNA transcription. Co-transformation of Cas9 and gRNA expression plasmids was exploited to overcome high-frequency mutation of cas9, allowing not only highly efficient gene deletion and insertion with plasmid-borne editing templates (efficiencies up to 60.0 and 62.5%, respectively) but also simple and time-saving operation. Furthermore, CRISPR/Cas9-mediated ssDNA recombineering was developed to precisely introduce small modifications and single-nucleotide changes into the genome of C. glutamicum with efficiencies over 80.0%. Notably, double-locus editing was also achieved in C. glutamicum. Microbial Cell Factories 2017, 16:205

MOST clears 5 biomedical key projects with a volume of 1.2 billion Yuan

The projects, which run until 2020, are: 1. Biomedical materials research and development and replacement of tissue and tissue remediation 2. Digital clinic equipment research and development 3. Major chronic non-communicable diseases prevention and control 4. Research on Prevention and Control of Reproductive Health and Major Birth Defects 5. Precision Medicine Research Each of the projects contains dozens of subprojects which are summarized under the MOST website China Bio news release, December 19, 2017

CAS QIBEBT group develops high-performance Mg/S battery

Batteries based on Mg anodes are safe, show high volumetric capacity, and inexpensive, but the lack of compatible electrolytes and suitable cathodes has restricted the development of rechargeable Mg batteries. A group at CAS Qingdao Institute of Bioenergy has developed to this end a new type of organic magnesium borate based electrolyte which was synthesized via a facile in-situ reaction of tris(hexafluoroisopropyl)borate [B(HFP)3], MgCl2 and Mg powders in 1,2-dimethoxyethane (DME). It features high Mg plating/stripping performance, such as high anodic stability up to 3.3 V (vs. Mg/Mg2+), high ionic conductivity of 5.58 mS·cm–1, low overpotential of 0.11 V for plating process and above 98% Coulombic efficiency. The electrolyte is well compatible with sulfur positive electrodes. Magnesium sulfur batteries using this electrolyte were demonstrated to endure more than 100 cycles without obvious capacity decay and to enable fast conversion process, even at the charging current density up to 500 mA·g–1. CAS news release, December 19, 2017

National Energy Administrytion of China explores combination of coal and biomass power generation

As the use of biomass energy is moving only slowly, the National Energy Administration and the Ministry of Environmental Protection have jointly started a pilot project on power generation coupling coal-incineration and biomass. Priority for cogeneration is limited to projects on coal-fired agricultural and forestry residues coupled with power generation technology projects, focusing on 13 major grain-producing provinces, and coal-fired waste incineration power generation technology projects, with emphasis on municipalities directly under the Central Government were landfill by sludge is difficult. The amount of manure and rubbish produced in China’s rural areas is estimated as 3.8 billion tons, and of straw at about 690 million tons. Biomass raw materials in rural areas are abundant, and 80% can be processed and utilized. The situation urban garbage is more complicated. China Bio news release, December 15, 2017

CAS Institute of Hydrobiology proposes algal biofuel production coupled to bioremediation

The group of Qiang WANG at the institute used waste streams from biomass power plants as nutrients for Chlorellac ultivation and found that Chlorella cultures produced 39 % more lipids and exhibited higher growth rates. The cultures reduced the NOx present in the flue gas and sequestered CO2, with a NOx reduction (DeNOx) efficiency of ∼100%, and a CO2 sequestration rate of 0.46 g L−1 d−1. The residual medium was almost nutrient-free and suitable for recycling. CAS news release, December 13, 2017

Chinese Academy of Sciences sets up Innovation Center in Bangkok

The CAS Innovation Cooperation Center (Bangkok) will bethe first overseas organization promoting global science, technology and innovation. The center will encourage Chinese innovative enterprises to come to Southeast Asia to build an innovative China-ASEAN community. Princess Maha Chakri Sirindhorn has visited CAS for many times to help the two countries cooperate on various fields such as microbiology, rail transit, and GPS technology. CAS news release, December 11, 2017

Scroll to top